CYP2C19基因多态性及血清NSE TNF-α与氯吡格雷治疗脑梗死临床转归的关系研究

doi:10.3969/j.issn.1006-6233.2025.06.02

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1265 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the association of serum neuron-specific enolase (NSE), tumor necrosis factor-α (TNF-α) and CYP2C19 gene polymorphism with clopidogrel treatment outcome in patients with cerebral infarction. Methods: A total of 104 patients with cerebral infarction in the hospital were enrolled from November 2021 to November 2023, and were treated with clopidogrel. CYP2C19 gene polymorphism and levels of NSE and TNF-α were detected, and the relationship with clopidogrel treatment outcome was analyzed. Results: There was a statistical difference in the distribution of CYP2C19 gene metabolic type between good prognosis group and poor prognosis group (P<0.05). The platelet aggregation rate and serum NSE and TNF-α levels in poor prognosis group were higher than those in good prognosis group, with statistical differences (P<0.05). The platelet aggregation rate, NSE and TNF-α levels revealed statistical differences among different metabolic types of CYP2C19 gene (P<0.05). The platelet aggregation rate, NSE and TNF-α of slow metabolic type and intermediate metabolic type were higher than those of fast metabolic type, with statistical differences (P<0.05). The proportion of patients with diabetes mellitus and age were higher or older in poor prognosis group than those in good prognosis group, with statistical differences (P<0.05). Multivariate Logistic regression analysis suggested that diabetes mellitus, CYP2C19 gene slow metabolic type, age, NSE and TNF-α were risk factors affecting the clopidogrel treatment outcome (P<0.05). ROC curve analysis revealed that the AUC, sensitivity and specificity of the combined evaluation of the five indicators were 0.843, 0.953 and 0.574 respectively. Conclusion: The poor prognosis of patients with cerebral infarction after clopidogrel treatment is related to the slow metabolic type of CYP2C19 gene and the levels of serum NSE and TNF-α, and has certain evaluated value on evaluating the treatment outcome.

Key words： Cerebral infarction Clopidogrel Neuron-specific enolase Tumor necrosis factor-α Clinical outcome

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHUANG Yuan
	FAN Weiwei
	LIU Dunhua

Cite this article:

ZHUANG Yuan,FAN Weiwei,LIU Dunhua. Relationship between CYP2C19 Gene Polymorphism Serum NSE TNF-α and Clinical Outcome of Clopidogrel Treatment in Cerebral Infarction[J]. HeBei Med, 2025, 31(6): 886-891.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.06.02 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I6/886

[1] Wang Z,Liu W,Ren Y,et al.Loss of life expectancy due to stroke and its subtypes in urban and rural areas in China,2005-2020[J].Stroke Vasc Neurol,2023,8(5):349.
[2] Zhao Y,Zhang X,Chen X,et al.Neuronal injuries in cerebral infarction and ischemic stroke:From mechanisms to treatment (Review)[J].Int Mol Med,2022,49(2):15.
[3] Kamarova M,Baig S,Patel H,et al.Antiplatelet Use in Ischemic Stroke[J].Ann Pharmacother,2022,56(10):1159-1173.
[4] Khandare P,Saluja A,Solanki RS,et al.Serum S100B and NSE levels correlate with infarct size and bladder-bowel involvement among acute ischemic stroke patients[J].Neurosci Rural Pract,2022,13(2):218-225.
[5] Biswas M,Hossain Ms,Ahmed Rupok T,et al.The association of CYP2C19 LoF alleles with adverse clinical outcomes in stroke patients taking clopidogrel:an updated meta-analysis[J].Clin Transl Sci,2024,17(4):13792.
[6] Isaksson E,Wester P,Laska AC,et al.Validation of the simplified modified rankin scale questionnaire[J].Eur Neurol,2020,83(5):493-499.
[7] Hidayat R,Nabilah Ra,Rasyid A,et al.Clopidogrel resistance among ischemic stroke patients and its risk factors in indonesia[J].Acta Med Acad,2022,51(1):29-34.
[8] Akkaif MA,Daud NAA,Sha'Aban A,et al.The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD)[J].Molecules,2021,26(7):1987.
[9] V Aswathy SP,Chandra KR,Jyothikrishna P,et al.Dosage optimization of clopidogrel via a precision medicine approach:the way forward[J].Pharmacogenomics,2022,23(3):195-206.
[10] Nawaz U,Noor M,Waheed A.Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance[J].Pak Med Assoc,2023,73(12):2388-2392.
[11] Shi GX,Zhao ZH,Yang XY,et al.Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region[J].Medicine (Baltimore),2021,100(6):24481.
[12] Gao L,Xie J,Zhang H,et al.Neuron-specific enolase in hypertension patients with acute ischemic stroke and its value forecasting long-term functional outcomes[J].BMC Geriatr,2023,23(1):294.
[13] Mochetti MM,Silva EGP,Correa AAF,et al.Neuron-specific enolase at admission as a predictor for stroke volume,severity and outcome in ischemic stroke patients:a prognostic biomarker review[J].Sci Rep,2024,14(1):2688.
[14] Han L,Wang Z,Yuan J,et al.Circulating leukocyte as an inflammatory biomarker:association with fibrinogen and neuronal damage in acute ischemic stroke[J].Inflamm Res,2023(16):1213-1226.
[15] Kollikowski AM,Pham M,Marz AG,et al.Platelet activation and chemokine release are related to local nutrophil-dominant inflammation during hyperacute human stroke[J].Transl Stroke Res,2022,13(3):364-369.